Drugs / 1/5 IPV-Al SSI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02280447 | Nov 2014 → Mar 2015 | — | Statens Serum Institut | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1/5 IPV-Al SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280447 ↗ |
| Known as | 1/5 IPV-Al | “Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI” PMID 28027810 ↗ Dec 2016 |
| Modality | Vaccine | “Intramuscular injection of 0.5 mL vaccine into deltoid muscle” NCT02280447 ↗ |
| Route | Intramuscular | “Intramuscular injection of 0.5 mL vaccine into deltoid muscle” NCT02280447 ↗ |